Enliven Therapeutics
Update in progressELVN (NasdaqGS)
- SectorHealthcare
- IndustryBiotechnology
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule inhibitors for cancer. Its programs include ELVN-001, a kinase inhibitor in Phase 1 for adults with chronic myeloid leukemia, and ELVN-002, a CNS-penetrant, irreversible HER2 inhibitor in Phase 1 for NSCLC and other HER2-mutant tumors. Founded in 2019, it is based in Boulder, Colorado.
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Richard A. Fair M.B.A.
- Founded2019
- Employees67
- Websitewww.enliventherapeutics.com
Identifiers
- ISINUS29337E1029
- FIGIBBG00CP3BDD4
- CUSIP29337E102
- CIK0001672619